Back to Search

A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who Are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial


  • Protocol Number: 202405124
  • Principal Investigator: Abboud, Ramzi
  • Cancer Types: Leukemia, Myeloma, and Hematologic

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

Protocol Interventions